THE COMBINED-ACTION OF ICI-D1694, 5-FLUORO-2'-DEOXYURIDINE AND 5-FLUOROURACIL IN INHIBITING THE GROWTH OF A HUMAN RENAL-CELL CARCINOMA CELL-LINE (RPMI-SE) IN-VITRO
- Authors:
- Published online on: January 1, 1994 https://doi.org/10.3892/ijo.4.1.137
- Pages: 137-141
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
In order to investigate possible interactions among ICI-D1694 (a new folate-analog thymidylate synthase inhibitor), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-fluorouracil (FUra), the effect of these agents alone and in 2-drug combinations against a human renal cell carcinoma cell line (RPMI-SE) in vitro was investigated. The median IC50's for cell growth inhibition for ICI-D1694, FdUrd and FUra were 4.00, 7.23 and 1,340 nM, respectively. To quantitatively assess the degree of agent-combined action for 2-agent combinations of the 3 drugs, data from combination experiments were fitted with a response surface mathematical model (Greco et al, Cancer Res 50: 5318-5327, 1990). In 3 experiments for each combination, moderate Loewe synergism was consistently shown for ICI-D1694/FdUrd, less prominent Loewe synergism was indicated for FdUrd/FUra; and Loewe additivity was shown for ICI-D1694/FUra. Studies in vitro to elucidate the mechanism of the interaction of ICI-D1694 + FdURD, and in vivo to establish possible therapeutic advantages are warranted.
